Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Dispute Resolution Process Should Be Less Structured, Merck Exec Says

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA should extend the deadline to challenge inspection findings and allow feedback for further clarification after a firm submits its response, Merck's Haggard says. The agency plans to share case studies of GMP issues to prevent future disputes.

You may also be interested in...

FDA's Overhaul Of GMP Oversight Will Include Numerous Targeted Guidances

The initiative to develop risk-based oversight of drug manufacturing will enter a new, less frenetic phase at its two-year anniversary in August. The project is a carryover from Deputy Commissioner Crawford's first term as acting head of FDA.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts